Bundeskanzler Gerhard Schröder besucht Boehringer Ingelheim
mehr
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Winterzeit - Hustenzeit / Husten ernst nehmen und rechtzeitig behandeln
Ingelheim (ots) - Husten dient dazu, unerwünschte Eindringlinge und krankhaft verändertes Sekret aus den unteren Atemwegen herauszuschleudern. Bei einer Erkältung sind es häufig Viren, die der Körper loswerden will. Die entzündeten Atemwege produzieren vermehrt Schleim, der nicht mehr vom normalen Reinigungssystem entfernt werden kann und deshalb abgehustet ...
mehrSimple VIRAMUNE(R) (nevirapine) Treatment Combination Shows Comparable Efficacy to Protease Inhibitor Combination
Glasgow, Scotland (ots-PRNewswire) - A simple anti-HIV treatment regimen of VIRAMUNE(R) (nevirapine) plus Combivir(TM) (3TC/ZDV)* showed comparable efficacy in reducing HIV below the limit of detection when compared to a regimen of the protease inhibitor nelfinavir* plus Combivir. These preliminary 36-week ...
mehrDie Menge anstelle der Substanz betrachten / Umdenkungsprozess für Kombinationsanalgetika fortgeschritten
Ingelheim (ots) - In der Schmerztherapie zeichnet sich derzeit ein Paradigmenwechsel ab: Pharmakologisch puristische Standpunkte, die für eine Behandlung mit Monosubstanzen plädieren, scheinen überholt. Heute spricht alles für eine Kombinationstherapie, die das komplexe Gefüge der Schmerzwahrnehmung und die ...
mehrLatebreaking Results of Mother-to-child HIV Transmission Study Shows Promise - VIRAMUNE Significantly Reduces HIV Transmission in Simple Regimen -
INGELHEIM, Germany (ots-PRNewswire) - One-year results of HIVNET 012, a trial conducted in Uganda by the National Institute of Allergy and Infectious Diseases (NIAID) HIV Prevention Trials Network (HIVNET), confirm preliminary findings that VIRAMUNE(R) (nevirapine) effectively reduced HIV transmission from ...
mehrLatebreaker Presentation on Atlantic Study Shows VIRAMUNE(R) (nevirapine) in a Simple Treatment Combination is Potent and Durable Against HIV
DURBAN, South Africa (ots-PRNewswire) - Findings from the Atlantic study indicate that VIRAMUNE + two nucleoside analogues has shown comparable efficacy to a protease inhibitor + two nucleoside analogues. The multi-centre, international Atlantic study is the first head-to-head comparison trial of agents in the ...
mehr
Data Show VIRAMUNE(R) (nevirapine) Combination Durably Suppresses HIV in Patients with Advanced HIV/AIDS
Durban, South Africa (ots-PRNewswire) - Study results demonstrating the significant potency of VIRAMUNE(R) (nevirapine, NVP) were presented today at the 13th International AIDS Conference in Durban, South Africa. Findings show VIRAMUNE-based treatment combinations suppressed HIV in the blood for up to one year in patients with advanced HIV disease and high baseline ...
mehrData Shows VIRAMUNE(R) (nevirapine) Well Tolerated and Effective for Prevention of Mother-to-child Transmission of HIV - More than 1,300 South African Women Participate in Landmark SAINT Trial
Durban, South Africa (ots-PRNewswire) - Results demonstrating that VIRAMUNE(R) (nevirapine) is well tolerated and effective in the prevention of mother-to-child transmission (MTCT) of HIV were presented today at the 13th International AIDS Conference. While VIRAMUNE is not currently indicated for the prevention ...
mehrBoehringer Ingelheim Offers VIRAMUNE(R) (nevirapine) Free of Charge to Developing Economies for the Prevention of HIV-1 Mother-to-Child Transmission
Ingelheim, Germany (ots-PRNewswire) - Boehringer Ingelheim announced today that VIRAMUNE(R) will be offered free of charge for a period of five years for the prevention of mother-to-child transmission (MTCT) of HIV-1 in developing economies. This initiative is part of Boehringer Ingelheim's commitment to the ...
mehr
Boehringer Ingelheim Joins Largest-Ever Global Program with United Nations Agencies to Accelerate Access to HIV/AIDS Care and Treatment in Developing Countries
Ingelheim, Germany (ots-PRNewswire) - Boehringer Ingelheim announced today that, as one of five leading pharmaceutical companies, it is joining a new initiative with United Nations organisations to explore ways to accelerate and improve the provision of HIV/AIDS-related care and treatment in developing ...
mehrBoehringer Ingelheim weist negative Beurteilung des Schmerzmittels Thomapyrin durch die Stiftung Warentest entschieden zurück
Ingelheim (ots) - Boehringer Ingelheim weist Kritik an der Wirksamkeit des Schmerzmittels Thomapyrin" mit allem Nachdruck zurück. Bei der Vorstellung des "Handbuchs Medikamente" der Stiftung Warentest am Mittwoch in Berlin waren entsprechende Behauptungen aufgestellt worden. Bei Thomapyrin handelt es ...
mehrResearchers Focus on Simple, Potent Therapies as Key Component to the Management of HIV Infection in the 21st Century
TAORMINA, Italy (ots-PRNewswire) - More than 750 European physicians convened here to discuss results of important clinical trials confirming the efficacy of the anti-HIV drug VIRAMUNE(R) (nevirapine) for the treatment of HIV-infected patients. Studies relating to adult and paediatric HIV treatment, as well ...
mehr
Zulassungserweiterung für Kombinationsschmerzmittel in den USA
Ingelheim (ots) - In den USA wurde die Zulassung der Wirkstoffkombination aus Acetylsalicylsäure, Paracetamol und Coffein für alle Formen der Migräne erweitert. Das Kombinationsschmerzmittel Excedrin Migraine, das in seiner Zusammensetzung den Thomapyrin(r) Schmerztabletten entspricht, ist somit als einziges rezeptfreies Schmerzmittel für die Behandlung der ...
mehrBoehringer Ingelheim Acquires New HIV/AIDS Drug from Pharmacia & Upjohn
INGELHEIM, Germany (ots-PRNewswire) - Boehringer Ingelheim and Pharmacia & Upjohn (NYSE: PNU) announced today that Boehringer Ingelheim has acquired worldwide rights for Pharmacia & Upjohn's investigational protease inhibitor, tipranavir. Under the agreement, Boehringer Ingelheim will have exclusive commercial rights to tipranavir in all markets worldwide. ...
mehrInternational HIV/AIDS Community Gains Access To Updated USA Treatment Guidelines / New Recommendations for First-Line Treatment
Ingelheim, Germany (ots-PRNewswire) - The Journal of the American Medical Association (JAMA) today published HIV/AIDS treatment guidelines updated by the International AIDS Society's (IAS) USA Panel on antiretroviral therapy use in adult HIV-1 infection. The updated guidelines reflect the increasingly important ...
mehr
Vorherige1234567